<DOC>
	<DOCNO>NCT02301494</DOCNO>
	<brief_summary>This study conduct Brian Poligone , MD PhD . The purpose study determine safety , effectiveness , tolerability two topical therapy , imiquimod fluocinonide , patient early stage Cutaneous T-cell Lymphoma ( CTCL ) .</brief_summary>
	<brief_title>Effectiveness Imiquimod Topical Cream Early Stage Cutaneous T-cell Lymphoma</brief_title>
	<detailed_description>The purpose study compare safety , effectiveness , tolerability two topical therapy , imiquimod fluocinonide , patient early stage CTCL .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Fluocinonide</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>1 . Male female subject age â‰¥18 year . 2 . Willing able give inform consent 3 . Diagnosis Mycosis Fungoides In case equivocal histological feature , diagnosis may confirm use clonal Tcell gamma gene rearrangement , detect PCR amplification primer set specific Tcell receptor gamma chain gene . 4 . Subjects must least one target lesion 5 . Subjects able comply study instruction , apply study medication direct attend visit . 6 . Females childbearing potential must negative urine pregnancy test randomization must agree use adequate method contraception ( abstinence , condom , hormonal therapy , barrier method ) study . 7 . Patients must otherwise healthy ECOG Performance status 0 1 . 8 . The patient must topical ( 2 week ) systemic therapy ( 4 week ) , radiotherapy ( 4 week ) phototherapy therapy ( 4 week ) Mycosis Fungoides within state number week prior start treatment . 9 . Eligible patient topical corticosteroid would prefer treatment include patient newly diagnose stage IA , IB , IIA disease , patient currently stable therapy , topical corticosteroid newly add regimen ( i.e . recurrence resistant lesion currently treat topical corticosteroid ) To eligible inclusion study subject must meet following criterion : 1 . Female pregnant , nursing infant , plan pregnancy study period . 2 . Have concomitant dermatologic medical condition ( ) may interfere investigator 's ability evaluate subject 's response study drug . 3 . Received investigational drug take part clinical study within one month prior study . 4 . Known reaction allergy test drug excipient . 5 . Presence major medical illness symptom clinically significant illness may influence study . 6 . Have reason , opinion investigator , interfere ability subject participate complete trial , place subject undue risk history drug , alcohol substance abuse factor limit ability cooperate comply protocol . 7 . Lesions genitals , axillae face select study treatment evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CTCL</keyword>
	<keyword>Mycosis Fungoides</keyword>
	<keyword>Cutaneous T-cell Lymphoma</keyword>
	<keyword>MF</keyword>
	<keyword>topical therapy</keyword>
	<keyword>early stage</keyword>
</DOC>